海納星空科技(08297.HK)一季度由盈轉虧330萬港元
格隆匯8月10日丨海納星空科技(08297.HK)公佈,截至2022年6月30日止三個月,公司錄得收益約1140萬港元,主要指源自(1)銷售女性內衣產品及其他輔助及配套產品;(2)提供美容服務;及(3)未動用預付套票所得收入的收入,較2021年同期錄得的收益約1300萬港元減少約12.3%,是由於COVID-19大流行致使零售銷售疲弱及香港政府實施的大流行預防措施導致銷售減少所致。
公司擁有人應占虧損約為330萬港元,而2021年同期則錄得公司擁有人應占溢利約70萬港元。此乃主要是由於銷量減少以及員工成本增加、使用權資產折舊及就推廣活動的營銷開支。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.